Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advagraf-based immunosuppression with or without everolimus in stable heart transplant recipients
2010-022941-72Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Feb 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tacrolimus and everolimus in Cardiac Rejection (2 arms), sponsored by Astellas Pharma. Primary endpoint: Renal function by eGFR (MDRD 4) at 52 weeks. Started Feb 2011; status: terminated.
02
Drugs
tacrolimuseverolimus
03
Conditions
Cardiac Rejection
Beyond the preview
Go deeper on 2010-022941-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022941-72.